The Effect of Thymol on Rat with Polycystic Ovary Syndrome

Subject Areas : Journal of Animal Biology

Sara Hojat jalali ¹ , Parichehre Yaghmaee ² , Azadeh Ebrahim-Habibi ³ , Nasim Hayati rodbari ⁴

1 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
2 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
3 - Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute
4 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

Received: 2022-01-17 Accepted : 2022-07-09 Published : 2023-02-20

Keywords: Thymol, Rat, Polycystic ovary syndrome, Estradiol-Valerat,

Abstract :

Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathy disorders in women and is one of the most important factors that lead to infertility. Thymol has many antimicrobial and antifungal effects. The aim of this study is to investigate the effect of thymol in the treatment of rats suffering from polycystic ovary syndrome (PCOS). This experimental study was conducted on female Wistar rats and the animals were divided into three groups: control, control (sham), and experimental. In order to induce PCOS, estradiol-valerate in the amount of 40 mg/4 ml was injected intramuscularly in 2 control and experimental groups for 25 days. Then, for 4 weeks, the control group and the experimental group were given grape seed oil, thymol in the amount of received 12 mg/kg in the amount of 1 cc through gavage. Finally, the animals were anesthetized by ether, the ovaries were removed for histological examination, and the blood serum was separated to examine the blood parameters. The findings of this study indicate that in the group The recipient of thymol increased the number of primary follicles (p < 0.01), developing and corpus luteum (p < 0.05), grafts (p < 0.001) and reduced cysts (p < 0.001) compared to the group. A control was observed. In the examination of blood parameters, it was found that in the group receiving thymol, there was a decrease in LH hormone (p < 0.01) and an increase in FSH hormone (p < 0.01). It was observed with the control group. The results of the research showed that probably the composition of thymol can be effective in the treatment of patients with polycystic ovary syndrome, although this case requires more studies.

References:

1. Abdul-Latif M.H., Mahmood A.K., Abayaji M.A. 2012. Adsorption of Thymol from aqueous solution using granulated surfactant initiated modified bentonite via packed column method. Ibn AL-Haitham Journal for Pure and Applied Science, 25(1):266-282.


2. Al-kataan M.A., Ibrahim M.A., Al-jammas M.H.H., Shareef Y.S., Sulaiman M.A. 2010. Serum Antioxidant Vitamins Changes in Women with Polycystic Ovarian Syndrome. Journal of the Bahrain. Medical Society, 22(2):68-71


3. Amini L., Tehranian N., Movahedin M., Ramezani-Tehrani F., Soltanghoraee H., 2016. Polycystic ovary morphology (PCOM) in estradiol valerate treated mouse model. International Journal of Women’s Health and Reproduction Sciences, 4(1): 7-13.


4. Andersen A. 2006. Final report on the safety assessment of sodium p-chloro-m- cresol, p-chloro-m-cresol, chlorothymol, mixed cresols, m-cresol, o-cresol, p-cresol, isopropyl cresols, thymol, o-cymen-5-ol, and carvacrol. International Journal of Toxicology, 25(2):29-127.


5. Arabbi P.R., Genovese M.I., Lajolo F.M. 2004. Flavonodis in vegetable foods commonly consumed in Brazil and estimated ingestion by the Brazillian population. Journal Agricultural Food Chemistry, 52(5):1124-1131.


6. Arya B.K.,Haq A.U.,Chaudhury K. 2012. Oocyte quality reflected by follicular fluid analysis in poly cystic ovary syndrome (PCOS): a hypothesis based on intermediates of energy metabolism. Medical Hypotheses,78(4):475-480.


7. Asgari S., Ani M., Naderi G.H.,Safari M.R., Mirzaalian A. 2001. Oxidized-LDL affinity for LDL receptor is increased in the presence of flavonoids. Journal of Molecular and Cellular Cardiology, 33(6):17-20.


8. Aybastıer Ö., Dawbaa S., Demir C., Akgün O., Ulukaya E., Arı F. 2018. Quantification of DNA damage products by gas chromatography tandem mass spectrometry in lung cell lines and prevention effect of thyme antioxidants on oxidative induced DNA damage. Mutation Fundamental and Molecular Mechanisms of Mutagenesis, 808: 1-9.


9. Burt S. 2004. Essential oils: their antibacterial properties and potential applications in foods a review, International Journal Food Microbiology, 94(3):223-253.


10. Brower M., Brennan K., Pall M., Azziz R, 2013. The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS. The Journal of Clinical Endocrinology and Metabolism, 98(12):15-28.


11. Chang R.J. 2007. The Reproductive Phenotype in Polycystic Ovary Syndrome: The Role of Androgens and Insulin in Hirsutism. Nature Clinical Practice, Endocrinology and Metabolism, 3(10):688-698.


12. Clifford T., Constantinou C.M., Keane K.M., West D.J., Howatson G., Stevenson E.J. 2017. The plasma bioavailability of nitrate and betanin from Betavulgaris rubra in humans. European Journal of Nutrition, 56 (3):1245-1254.


13. Dahan M.H., Morris D.V. 2013. The impact of body mass index (BMI) on the incidence of type 2 diabetes (DMII) in women with and without polycystic ovary syndrome (PCOS). Fertility and Sterility, 100(3): 348-349.


14. Ding E.L., Song Y., Manson J.E., Buring J.E., Liu S. 2007. Plasma sex steroid hormones and risk of developingtype 2 diabetes in women: a prospective study. Diabetologia, 50(10): 2076-2084.


15. 15. Dumesic D.A., Schramm R.D., Abbott D.H., 2005. Early origins of polycystic ovary syndrome (PCOS). Reproduction, Fertility and Development, 17(3):349-360.


16. 16. Ehrmann D.A. 2005. Polycystic ovary syndrome. The New England Journal Medicine, 352(12):1223-1236.


17. Escobar-Morreale H.F., Carmina E., Dewailly D., Gambineri A., Kelestimur F., Moghetti P., Pugeat M., Qia J., Wijeyaratne C.N.,Witchel S.F., Norman RJ., 2012. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society.Human Reproduction Update, 18(2):146-170.


18. Imaida K., Fukushima S., Shirai T., Ohtani M., Nakanishi K., Ito N. 1983. Promoting activities of butylated hydroxyanisole and butylated hydroxytoluene on 2-stage urinary bladder carcinogenesis and inhibition of γ-glutamyl transpeptidase-positive foci development in the liver of rats. Carcinogenesis,4(7):895-899.


19. Kemertelidze E., Sagareishvili T., Syrov V., Khushbaktova Z., Tsutskiridze L., Kurashvili R., 2012. Saturin - effective vegetative remedy in treatment of type 2 diabetes mellitus. Georgian Medical News, 203:47-52.


20. Lo Piparo E., Scheib H., Frei N., Williamson G., Grigorov M., Chou C.J. 2008. Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase. Journal of Medicinal Chemistry, 51(12):3555-35561.


21. Nostro A., Roccaro A.S., Bisignano G., Marino A., Cannatelli M.A., Pizzimenti F.C. 2007. Effects of oregano,carvacrol and thymol on Staphylococcus aureus and Staphylococcus epidermidis biofilms. Journal of Medical Microbiology, 56(4): 519-523.


22. Ouladsahebmadarek E., Khaki A., Farzadi L., Zahedi A. 2013. Nutrition with polyunsaturated fatty acid and lower carbohydrate diet has controlled polycystic ovarian syndrome, on poly cystic ovarian (PCO) induces rats. Life Science Journal, 10(1):1171-1175.


23. Sabu M.C., Smith K., Kuttan R. 2002. Antidiabetic activity of green tea polyphenol. Journal of Ethnopharmacology, 83(1-2):109-116.


24. Sakai I., Izumi S.I., Murano T., Okuwaki S., Makino T., Suzuki T. 2001. Presence of aldose reductase inhibitors in tea leaves. Japanese Journal of Pharmacology, 85(3):322-326.


25. Shareef Y.S., Sulaiman M.A. 2010. Serum Antioxidant Vitamins Changes in Women with Polycystic Ovarian Syndrome. Journal of the Bahrain Medical Society, 22(2):68-71.


26. Suntres Z.E., Coccimiglio J., Alipour M. 2015. The bioactivity and toxicological actions of carvacrol. Critical Reviews in Food Science and Nutrition, 55(3):304-318.


27. Stener-Victorin E.,Kobayashi R.,Watanabe O., Lundeberg T., Kurosawa M. 2012. Effect of electro-acupuncture stimulation of different frequencies and intensities on ovarian blood flow in anaesthetized rats with steroid-induced polycystic ovaries. 26:2-16.


28. Stener-Victorin E., Lundeberg T., Waldenstrom U., Manni L., Aloe L., Gunnarsson S., Janson P.O. 2000. Effects of electro-acupuncture on nerve growth factor and ovarian morphology in rats with experimentally induced polycystic ovaries. Biology of Reproduction, 63(5):1497-1503.


29. Wu C., Wei K., Jiang Z. 2017. 5α-reductase activityin women with polycystic ovary syndrome: asystematic review and meta-analysis. Reproductive Biology and Endocrinology, 15(1): 21-30.


30. Zafari Zanganeh F., Minaee B., Amirzargar A., Ahangarpour A., Mousavizadeh K. 2010. Effects of chamomile extract on biochemical and clinical parameters in a rat model of polycystic ovary syndrome. Journal of Reproduction and Infertility, 11(3):169-174.


31. Zhang Y., Hu M., Meng F., Sun X., Xu H., Zhang J., Cui P., Morina N., Li X., Li W., Wu X.K., Brännström M., Shao R., Billig H. 2017. Metformin ameliorates uterine defects in a rat model of polycystic ovary syndrome. EBioMedicine,18:157-170.